Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis

Shimamoto,Yuji; Nukatsuka,Mamoru; Takechi,Teiji; Fukushima,Masakazu

doi:10.3892/ijmm.2015.2427

Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis

Authors:
- Yuji Shimamoto
- Mamoru Nukatsuka
- Teiji Takechi
- Masakazu Fukushima
View Affiliations

Affiliations: Translational Research Laboratory, Taiho Pharmaceutical Co., Ltd., Uchikanda, Chiyoda-ku, Tokyo 101-0047, Japan, Translational Research Laboratory, Taiho Pharmaceutical Co., Ltd., Kawauchi-Cho, Tokushima‑shi, Tokushima 771-0194, Japan, The Japan-Multinational Trial Organization, Naka-ku, Nagoya-shi, Aichi 460-0002, Japan
Published online on: December 10, 2015 https://doi.org/10.3892/ijmm.2015.2427
Pages: 319-328
Copyright: © Shimamoto et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To establish the individualized treatment of patients with colorectal cancer, factors associated with chemotherapeutic effects should be identified. However, to the best of our knowledge, few studies are available on this topic, although it is known that the prognosis of patients and sensitivity to chemotherapy depend on the location of the tumor and that the tumor location is important for individualized treatment. In this study, primary tumors obtained from 1,129 patients with colorectal cancer were used to measure the mRNA expression levels of the following genes associated with the effects of standard chemotherapy for colorectal cancer: 5-fluorouracil (5-FU)-related thymidylate synthase (TYMS), dihydropyrimidine dehydrogenase (DPYD) and thymidine phosphorylase (TYMP); folate-related dihydrofolate reductase (DHFR), folylpolyglutamate synthase (FPGS) and gamma-glutamyl hydrolase (GGH); irinotecan-related topoisomerase I (TOP1); oxaliplatin-related excision repair cross-complementing 1 (ERCC1); biologic agent-related vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). Large-scale population analysis was performed to determine the association of gene expression with the clinicopathological features, in particular, the location of the colorectal cancer. From the results of our analysis of the mRNA expression of these 10 genes, we noted the strongest correlation between DPYD and TYMP, followed by TYMS and DHFR. The location of the colorectal cancer was classified into 4 regions (the right‑ and left-sided colon, rectosigmoid and rectum) and was compared with gene expression. A significant difference in all genes, apart from VEGF, was noted. Of the remaining 9 genes, the highest expression of TYMS and DPYD was observed in the right‑sided colon; the highest expression of GGH and EGFR was noted in the left-sided colon; the highest expression of DHFR, FPGS, TOP1 and ERCC1 was noted in the rectosigmoid, whereas TYMP expression was approximately equivalent in the right-sided colon and rectum, and higher than that in other locations. The data generated from this study may prove to be useful for the development of individualized chemotherapeutic treatments for patients with colorectal cancer, and will mean that the tumor location is taken into account.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar
2	Meyerhardt JA and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005. View Article : Google Scholar : PubMed/NCBI
3	Wilson PM, Danenberg PV, Johnston PG, Lenz HJ and Ladner RD: Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nat Rev Clin Oncol. 11:282–298. 2014. View Article : Google Scholar : PubMed/NCBI
4	van Kuilenburg AB: Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 40:939–950. 2004. View Article : Google Scholar : PubMed/NCBI
5	Toi M, Atiqur Rahman M, Bando H and Chow LW: Thymidine phosphorylase (platelet-derived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol. 6:158–166. 2005. View Article : Google Scholar : PubMed/NCBI
6	Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB and Danenberg PV: Colorectal tumors responding to 5-fluoro-uracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phos-phorylase. Clin Cancer Res. 6:1322–1327. 2000.PubMed/NCBI
7	Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph D, et al: Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol. 19:915–919. 2008. View Article : Google Scholar : PubMed/NCBI
8	Laufman LR, Krzeczowski KA, Roach R and Segal M: Leucovorin plus 5-fluorouracil: an effective treatment for metastatic colon cancer. J Clin Oncol. 5:1394–1400. 1987.PubMed/NCBI
9	Sakamoto E, Tsukioka S, Oie S, Kobunai T, Tsujimoto H, Sakamoto K, Okayama Y, Sugimoto Y and Oka T, Fukushima M and Oka T: Folylpolyglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity. Biochem Biophys Res Commun. 365:801–807. 2008. View Article : Google Scholar
10	Pommier Y: Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 6:789–802. 2006. View Article : Google Scholar : PubMed/NCBI
11	Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV and Lenz HJ: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 19:4298–4304. 2001.PubMed/NCBI
12	Bohanes P, Labonte MJ and Lenz HJ: A review of excision repair cross-complementation group 1 in colorectal cancer. Clin Colorectal Cancer. 10:157–164. 2011. View Article : Google Scholar : PubMed/NCBI
13	Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar
14	Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 23:2445–2459. 2005. View Article : Google Scholar : PubMed/NCBI
15	Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N and Iacopetta B: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet. 355:1745–1750. 2000. View Article : Google Scholar : PubMed/NCBI
16	Iacopetta B: Are there two sides to colorectal cancer? Int J Cancer. 101:403–408. 2002. View Article : Google Scholar : PubMed/NCBI
17	Gervaz P, Bucher P and Morel P: Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol. 88:261–266. 2004. View Article : Google Scholar : PubMed/NCBI
18	Söreide K, Janssen EA, Söiland H, Körner H and Baak JP: Microsatellite instability in colorectal cancer. Br J Surg. 93:395–406. 2006. View Article : Google Scholar : PubMed/NCBI
19	Fukushima M, Morita M, Ikeda K and Nagayama S: Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors. Int J Mol Med. 12:839–844. 2003.PubMed/NCBI
20	Fukui Y, Oka T, Nagayama S, Danenberg PV, Danenberg KD and Fukushima M: Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med. 22:709–716. 2008.PubMed/NCBI
21	General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus. Japanese Society for Cancer of the Colon and Rectum: 7th edition. Kanehara & Co, Ltd; Kanehara, Tokyo; 2006
22	Lord RV, Salonga D, Danenberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, et al: Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg. 4:135–142. 2000. View Article : Google Scholar : PubMed/NCBI
23	Heid CA, Stevens J, Livak KJ and Williams PM: Real time quantitative PCR. Genome Res. 6:986–994. 1996. View Article : Google Scholar : PubMed/NCBI
24	Gibson UE, Heid CA and Williams PM: A novel method for real time quantitative RT-PCR. Genome Res. 6:995–1001. 1996. View Article : Google Scholar : PubMed/NCBI
25	Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, Vallböhmer D, Park S, Danenberg KD, Takasaki K and Danenberg PV: Vascular endothelial growth factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res. 12:29–33. 2006. View Article : Google Scholar : PubMed/NCBI
26	Ichikawa W, Uetake H, Shirota Y, Yamada H, Takahashi T, Nihei Z, Sugihara K, Sasaki Y and Hirayama R: Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Br J Cancer. 89:1486–1492. 2003. View Article : Google Scholar : PubMed/NCBI
27	Yoshinare K, Kubota T, Watanabe M, Wada N, Nishibori H, Hasegawa H, Kitajima M, Takechi T and Fukushima M: Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci. 94:633–638. 2003. View Article : Google Scholar : PubMed/NCBI
28	Inokuchi M, Uetake H, Shirota Y, Yamada H, Tajima M and Sugihara K: Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. Cancer Chemother Pharmacol. 53:391–396. 2004. View Article : Google Scholar : PubMed/NCBI
29	Uchida K, Danenberg PV, Danenberg KD and Grem JL: Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. BMC Cancer. 8:3862008. View Article : Google Scholar : PubMed/NCBI
30	Sameshima S, Tomozawa S, Kojima M, Koketsu S, Motegi K, Horikoshi H, Okada T, Kon Y and Sawada T: 5-Fluorouracil-related gene expression in primary sites and hepatic metastases of colorectal carcinomas. Anticancer Res. 28(3A): 1477–1481. 2008.PubMed/NCBI
31	Kumamoto K, Kuwabara K, Tajima Y, Amano K, Hatano S, Ohsawa T, Okada N, Ishibashi K, Haga N and Ishida H: Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis. Oncol Lett. 3:983–989. 2012.PubMed/NCBI
32	Goto T, Shinmura K, Yokomizo K, Sakuraba K, Kitamura Y, Shirahata A, Saito M, Kigawa G, Nemoto H, Sanada Y and Hibi K: Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer. Anticancer Res. 32:1757–1762. 2012.PubMed/NCBI
33	Uetake H, Ishikawa T, Matsui S and Sugihara K: Gene expression analysis as a biomarker study for ACTS-CC trial (TRICC0706), a phase III trial for adjuvant chemotherapy of S-1 and UFT/LV against stage III colon cancer in Japan. Cancer Res. 72(8 Suppl): 45162012. View Article : Google Scholar
34	Kawakami K, Ooyama A, Ruszkiewicz A, Jin M, Watanabe G, Moore J, Oka T, Iacopetta B and Minamoto T: Low expression of gamma-glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island methylator phenotype. Br J Cancer. 98:1555–1561. 2008. View Article : Google Scholar : PubMed/NCBI
35	Sadahiro S, Suzuki T, Tanaka A, Okada K, Nagase H and Uchida J: Association of right-sided tumors with high thymidine phosphorylase gene expression levels and the response to oral uracil and tegafur/leucovorin chemotherapy among patients with colorectal cancer. Cancer Chemother Pharmacol. 70:285–291. 2012. View Article : Google Scholar : PubMed/NCBI
36	Ricciardiello L, Ceccarelli C, Angiolini G, Pariali M, Chieco P, Paterini P, Biasco G, Martinelli GN, Roda E and Bazzoli F: High thymidylate synthase expression in colorectal cancer with micro-satellite instability: Implications for chemotherapeutic strategies. Clin Cancer Res. 11:4234–4240. 2005. View Article : Google Scholar : PubMed/NCBI
37	Jensen SA, Vainer B, Kruhøffer M and Sørensen JB: Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression. BMC Cancer. 9:252009. View Article : Google Scholar : PubMed/NCBI
38	Sinicrope FA, Rego RL, Halling KC, Foster NR, Sargent DJ, La Plant B, French AJ, Allegra CJ, Laurie JA, Goldberg RM, et al: Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin Cancer Res. 12:2738–2744. 2006. View Article : Google Scholar : PubMed/NCBI
39	Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, Popovici V, Vecchione L, Gerster S, Yan P, et al: Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 25:1995–2001. 2014. View Article : Google Scholar : PubMed/NCBI
40	Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ, et al: Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 107:dju4272015. View Article : Google Scholar : PubMed/NCBI
41	Kotake K, Honjo S, Sugihara K, Kato T, Kodaira S, Takahashi T, Yasutomi M, Muto T and Koyama Y: Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum. 46(Suppl): S32–S43. 2003.PubMed/NCBI
42	Sakamoto K, Machi J, Prygrocki M, Watanabe T, Hosoda S, Sugano M, Tomiki Y and Kamano T: Comparison of characteristics and survival of colorectal cancer between Japanese-Americans in Hawaii and native Japanese in Japan. Dis Colon Rectum. 49:50–57. 2006. View Article : Google Scholar